Bazedoxifene Acetate
FDA-approved product (tablet, oral).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Postmenopausal osteoporosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Selective estrogen receptor modulators
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Bazedoxifene Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Tubocurarine ChlorideExisting use: Curare alkaloids51.4% AI-predicted activityagainst E. coliNo documented evidence found
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more51.4% AI-predicted activityagainst E. coli50+ registered studies
- BrigatinibExisting use: Neoplasm, Non-small cell lung carcinoma51.2% AI-predicted activityagainst E. coli48 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more51.1% AI-predicted activityagainst E. coli50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more51.0% AI-predicted activityagainst E. coli50+ registered studies
- EntrectinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma50.9% AI-predicted activityagainst E. coli46 registered studies
- DasatinibExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more50.8% AI-predicted activityagainst E. coli50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more50.5% AI-predicted activityagainst E. coli35 registered studies
- IvosidenibExisting use: Acute myeloid leukemia, Cholangiocarcinoma50.4% AI-predicted activityagainst E. coli50+ registered studies
- Thiamine HydrochlorideExisting use: Anemia (phenotype), Chronic kidney disease, Encephalopathy and 2 more50.4% AI-predicted activityagainst E. coli50+ registered studies
- VibegronExisting use: Overactive bladder, Polyuria, Urgency urinary incontinence and 1 more50.4% AI-predicted activityagainst E. coli16 registered studies
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma50.3% AI-predicted activityagainst E. coli3 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
NCT00242710 · start 2005-09
Registered record
- Registry ID
- NCT00242710
- Conditions
- Endometrial Hyperplasia; Osteoporosis
- Interventions
- Bazedoxifene/Conjugated Estrogen; Bazedoxifene/Conjugated Estrogen; CE 0.45 mg/MPA 1.5mg; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2008-09
- Enrolment
- 1,083
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndometrial Hyperplasia; OsteoporosisInterventionBazedoxifene/Conjugated Estrogen; Bazedoxifene/Conjugated Estrogen; CE 0.45 mg/MPA 1.5mg; PlaceboPhasePhase 3Registry statusCompletedStudy Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.
NCT00238745 · start 2003-08
Registered record
- Registry ID
- NCT00238745
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Bazedoxifene; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-08
- Completion
- 2007-03
- Enrolment
- 375
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopausal OsteoporosisInterventionBazedoxifene; PlaceboPhasePhase 2Registry statusCompletedStudy Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
NCT00675688 · start 2002-04
Registered record
- Registry ID
- NCT00675688
- Conditions
- Endometrial Hyperplasia; Osteoporosis
- Interventions
- Bazedoxifene/Conjugate Estrogens (CE); Raloxifene; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-04
- Completion
- 2006-01
- Enrolment
- 3,544
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndometrial Hyperplasia; OsteoporosisInterventionBazedoxifene/Conjugate Estrogens (CE); Raloxifene; PlaceboPhasePhase 3Registry statusCompletedStudy Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
NCT00205777 · start 2001-12
Registered record
- Registry ID
- NCT00205777
- Conditions
- Osteoporosis
- Interventions
- Bazedoxifene Acetate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-12
- Completion
- 2010-09
- Enrolment
- 7,609
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoporosisInterventionBazedoxifene Acetate; PlaceboPhasePhase 3Registry statusCompletedStudy Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
NCT00481169 · start 2001-07
Registered record
- Registry ID
- NCT00481169
- Conditions
- Osteoporosis
- Interventions
- Bazedoxifene Acetate (TSE-424)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-07
- Completion
- 2004-09
- Enrolment
- 1,742
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoporosisInterventionBazedoxifene Acetate (TSE-424)PhasePhase 3Registry statusCompleted